Mechanistic overlap between chronic lung injury and cancer: ERS Lung Science Conference 2017 report

Gosens, Reinoud; Giangreco, Adam; Chambers, Rachel C.

doi:10.1183/16000617.0060-2017

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic lung injury, such as chronic obstructive pulmonary disease, is strongly associated with the development of lung cancer, and this mechanistic overlap has attracted increasing attention ( 72 , 73 ). Chemotherapy, surgery, medication treatment for lung cancer, and even treatment for other types of cancer can lead to lung injury ( 74 – 77 ).…”

Section: Other Biological Functions Of Mg53 May Contribute To Cancer ...mentioning

confidence: 99%

Is MG53 a potential therapeutic target for cancer?

Du,

Li,

2023

Front. Endocrinol.

View full text Add to dashboard Cite

Cancer treatment still encounters challenges, such as side effects and drug resistance. The tripartite-motif (TRIM) protein family is widely involved in regulation of the occurrence, development, and drug resistance of tumors. MG53, a member of the TRIM protein family, shows strong potential in cancer therapy, primarily due to its E3 ubiquitin ligase properties. The classic membrane repair function and anti-inflammatory capacity of MG53 may also be beneficial for cancer prevention and treatment. However, MG53 appears to be a key regulatory factor in impaired glucose metabolism and a negative regulatory mechanism in muscle regeneration that may have a negative effect on cancer treatment. Developing MG53 mutants that balance the pros and cons may be the key to solving the problem. This article aims to summarize the role and mechanism of MG53 in the occurrence, progression, and invasion of cancer, focusing on the potential impact of the biological function of MG53 on cancer therapy.

show abstract

Section: Other Biological Functions Of Mg53 May Contribute To Cancer ...mentioning

confidence: 99%

Is MG53 a potential therapeutic target for cancer?

Du,

Li,

2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Among females, lung cancer has surpassed breast cancer as the leading cause of cancer death in more developed countries. Now it is well accepted that many lung diseases such as www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i10.181 cancer, COPD, asthma and IPF are inflammatory lung diseases that share the common pathway of inflammation and aberrant repair (2) Inflammation is the natural response of body to any sort of injury(pathogen, allergen, toxins, products from tissue damage),and is mediated by the innate and adaptive immune systems. Innate immunity together with adaptive immunity makes up the natural host defensive barrier; composed of epithelial endothelial barriers, germline encoded receptors, immune organs, immune inflammatory cells, and cytokines.…”

Section: Introductionmentioning

confidence: 99%

Neutrophil Lymphocyte Ratio (NLR) in Patients with Lung Cancer - An Index of Cancer Related Systemic Inflammation

Thomas¹

2018

jmscr

View full text Add to dashboard Cite

Introduction: Neutrophilia has been associated with many chronic inflammatory lung diseases, lung cancer and systemic inflammatory diseases. A common denominator of inflammation in these entities is Th 17 type of CD4+T cell adaptive immunity. Neutrophil infiltration of tumour microenvironment and peripheral blood neutrophilia has become a focus of attraction in recent research on chronic inflammatory diseases. Many studies have shown that increased neutrophil:lymphocyte ratio(NLR) and advanced lung cancer inflammation index (ALI) are poor prognostic indicators in cancers. Aims: This study aims to find out the neutrophil: lymphocyte ratio in lung cancer patients. Materials and Methods: This study is a retrospective analysis conducted in the Department of Pulmonary medicine in a tertiary care centre in south Kerala. The case records of 50 patients, histologically diagnosed as lung cancer were analysed. NLR was calculated from routine blood examination results. Results: The total number of patients included in the study was 50.The most common histological type of lung cancer was adenocarcinoma in both males and females of all ages. Neutrophil lymphocyte ratio was high in all patients, irrespective of the histological type. Mean value of NLR was 5.33 (reference range, 2.15 or less) (1) Conclusion: This study shows that neutrophils are the predominant leukocytes in peripheral blood of lung cancer patients, supporting the concept of ongoing injury and repair processes in the pathogenesis of inflammation in lung cancer. NLR is a simple and inexpensive bed side biomarker of systemic inflammation in lung cancer patients.

show abstract

Repurposing Drugs for Cancer Prevention

Choradia,

Szabo

2024

Cancer J

View full text Add to dashboard Cite

The development of agents for cancer prevention is a lengthy process requiring a delicate balance between the safety and tolerability of potential interventions and effectiveness in preventing future cancer. Individuals at risk for a specific cancer are frequently at risk for multiple types of cancer as well as other chronic diseases, especially ones associated with aging. Shared environmental exposures, genetic predisposition, metabolic factors, and commonalities in pathogenesis suggest opportunities for combined targeting of cancer and other chronic diseases. Examples discussed here include mechanisms shared between various cancers and obesity, diabetes, and cardiovascular disease.

show abstract

Mechanistic overlap between chronic lung injury and cancer: ERS Lung Science Conference 2017 report

Cited by 3 publications

References 11 publications

Is MG53 a potential therapeutic target for cancer?

Is MG53 a potential therapeutic target for cancer?

Neutrophil Lymphocyte Ratio (NLR) in Patients with Lung Cancer - An Index of Cancer Related Systemic Inflammation

Repurposing Drugs for Cancer Prevention

Contact Info

Product

Resources

About